Brian Kushner, MD
Memorial Sloan Kettering Cancer Center
12
12
5
N/A
0
15
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+18 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
AeRang Kim, MD, PhD
Children's National Research Institute
Shared therapeutic areas:
Ka Yan Ho, phd
The Hong Kong Polytechnic University
Shared therapeutic areas:
Mia Weiss, M.D.
Washington University School of Medicine
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Nai-Kong V. Cheung, MD, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Matthew Krebs, Dr
The Christie Hospital
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Francois Benard, MD
BC Cancer
Shared therapeutic areas:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Giselle Sholler, MD
Beat Childhood Cancer at Atrium Health
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
A Study of N9 Chemotherapy in Children With Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Naxitamab and GM-CSF in People With Neuroblastoma
All 12 trials loaded